Trials / Completed
CompletedNCT01309854
Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects
An Open-Label, Single Center Study to Assess the Pharmacokinetics of Pioglitazone in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the drug interaction between fostamatinib and pioglitazone by comparing the safety, tolerability and plasma concentration of pioglitazone when administered alone and with fostamatinib in healthy subjects.
Conditions
- Rheumatoid Arthritis
- Healthy Volunteers
- Pharmacokinetics
- Pioglitazone
- Drug-drug Interaction
- Amount of Pioglitazone in Blood
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fostamatinib | oral tablets, 100mg (2 X 50mg) twice daily for 8 days |
| DRUG | pioglitazone | oral tablets, 30mg single dose per period |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2011-05-01
- Completion
- 2011-05-01
- First posted
- 2011-03-07
- Last updated
- 2011-07-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01309854. Inclusion in this directory is not an endorsement.